BioOutsource To Open New Biosimilar Centre of Excellence in Glasgow as Global Demand Surges
|| Print ||
|Wednesday, 05 February 2014 10:00 (UTC + 1)|
Already a Leader in Biosimilar Services, Company’s Biosimilars Analysis Capacity to Double with Addition of New Facility
Glasgow, Scotland, February 5, 2014 / B3C newswire / – BioOutsource Ltd. (“BioOutsource”), a global leader in biologics contract testing and biosimilar characterization for the biopharmaceutical industry, today announced the opening of a new Biosimilar Centre of Excellence in Glasgow. The new facility will double the company’s capacity for the analysis of biosimilar monoclonal antibodies.
“The global biosimilar market is predicted to more than double in size to $19 billion by 2018. The increasing demand for our biosimilars services and the addition of several new clients has made this a necessary investment for 2014, as our revenues in this market have quadrupled in the last 18 months,” commented BioOutsource CEO, Gerry MacKay. “We are delighted to announce the opening of this new, state-of-the-art Biosimilar Centre of Excellence in Glasgow.”
The Biosimilar Centre of Excellence is located on the West of Scotland Science Park in Glasgow, adjacent to the existing BioOutsource facility. The new operation will consist of approximately 40 laboratory and R&D scientists creating an estimated 20 new jobs.
“We are committed to providing our clients with excellent levels of service and technical support” continued Mr. MacKay. “In 2013 we increased our headcount by 30% as we added new services to our portfolio and we anticipate repeating this expansion in the first quarter of this year. We have now worked with no fewer than 30 global biosimilar companies who use our range of off-the-shelf assays for the comparability, stability and lot release testing of their biosimilars.”
Mr. MacKay concluded, “Importantly, we feel that our growth in this fast emerging market is driven by our extensive investments in an R&D program, which is developed and refined in conjunction with all our global clients.”
Dr. Verna McErlane